PharmaJet, the maker of innovative, needle-free injection technology, announced on Wednesday that it has named Dr Marie Mazur as its new director.

Dr Mazur is a global business executive with more than 30 years of experience growing revenue and profits for major vaccine and pharmaceutical companies. Since 2006, Dr Mazur held executive roles at the influenza vaccine company Seqirus, which is part of CSL Limited. Most recently she was vice president, Pandemic Response Solutions where she had global commercial responsibility for pandemic and pre-pandemic contracts. In January 2018, she was selected as co-chair of BDPAC (Bio-Defense Policy Advisory Committee) at the Biotechnology Innovation Organization, working with biotechnology company leaders invested in the development and manufacture of medical countermeasures. Prior to joining CSL, she held successive global commercial leadership positions at GlaxoSmithKline Biologicals, 3M Pharmaceuticals and Sanofi Pasteur.

Ron Lowy, executive chairman, PharmaJet Inc said, 'We are very pleased to welcome Dr Mazur to the PharmaJet board of directors. Her operational and strategic expertise with major vaccine and pharmaceutical companies as well as pandemic vaccine response solutions is an extraordinary addition to our board.'